alexa
Reach Us +44-1904-929220
Serum β2-Microglobulin Levels in Patients with Various Solid Cancer | OMICS International | Abstract
ISSN-2155-9929

Journal of Molecular Biomarkers & Diagnosis
Open Access

Like us on:

Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Research Article

Serum β2-Microglobulin Levels in Patients with Various Solid Cancer

Kesheng Li1*, Huifeng Du1, Xiaowen Lian1, Ming Yuan1, Qinjiang Liu2, Suisheng Yang3, Xuezhong Chen4, Rong Yang5 and Wenhua Ye1

1Department of Medicine Biotechnology, Medicine and Science Research Institute of Gansu province, Lanzhou, China

2Department of Nosecone and Carotid Surgery, Tumor Hospital of Gansu province, Lanzhou, China

3Department of Breast Surgery, Tumor Hospital of Gansu province, Lanzhou, China

4Department of Chest Surgery, Tumor Hospital of Gansu province, Lanzhou, China

5Department of pathology, Tumor Hospital of Gansu province, Lanzhou, China

*Corresponding Author:
Kesheng Li
Department of Medicine Biotechnology;
Medicine and Science Research Institute of Gansu;
province, Lanzhou, 730050, China;
Tel: 86-931-2614521;
Fax: 86-931-2614551;
E-mail: [email protected]

Received date: November 23, 2011; Accepted date: December 26, 2011; Published date: January 04, 2012

Citation: Li K, Du H, Lian X, Yuan M, Liu Q, et al. (2012) Serum β2—Microglobulin Levels in Patients with Various Solid Cancer. J Mol Biomark Diagn S2:007. doi:10.4172/2155-9929.S2-007

Copyright: © 2012 Li K, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited

Abstract

Background: The level of β2-M has become one of the most important prognostic factors and predictors of survival in patients with certain caner. The aim of this study was to investigate the serum levels of β2-M in patients with various solid cancers, to find the prognostic and predictive value of serum β2-M level elevating in patients with solid cancer. Methods: A total of 1158 serum from 774 patients with various solid cancer and 384 patients with various solid benign tumor patients were analyzed by β2-microglobulin ELISA kit, the data were analyzed by using statistical 36 packages for sciences (spss11.0) software. Results: In patients with thyroid cancer, patients with breast cancer and that with liver cancer the mean β2-microglobulin levels and positive rate were significantly higher than that in controls (p<0.05, p<0.01). In patients with other solid cancer including gastric, esophagus, intestinal and lung cancer the mean β2-microglobulin levels have no significant difference compared with that in controls (p>0.05), and the positive rats were not significantly different compared with that in controls (p>0.05) except the patients with esophagus cancer in which the positive rate was significantly different compared with that in controls (p < 0.01). In female breast cancer patients the mean β2- microglobulin levels and the positive rate were significantly higher than that in breast benign tumor patients (p<0.05: p<0.05), no significant difference stages and clinical stages. In thyroid cancer patients the mean β2-microglobulin levels and the positive rate were significantly higher than that in thyroid benign tumor patients (p< 0.05, p< 0.01), no significant difference in sex, ages, clinical stages, but the mean β2-microglobulin levels and the positive rate were significantly higher in patients with follicular thyroid cancer than that in patients with mamillary thyroid 54 cancer patients. Conclusion: β2-M is an important tumor marker in breast, thyroid and liver cancer that would be one of assistantly diagnostic factors in patients with these cancers.

Recommended Conferences

15th Global Biomarkers and Clinical Research Summit

Vienna, Austria

2nd International Conference on Biomarkers and Cancer Targets

Capetown, South Africa
Share This Page
Top